How the U.S. Can Beat China in Biotech
Lumen Bioscience's Brian Finrow breaks down China's biotech playbook and explores ways the U.S. can adapt it for its own continued success.
China's emergence as a biopharma powerhouse has become a hot topic in the industry, with growing numbers of biotech startups, a surge in drug approvals, and major licensing deals flowing westward from China.
There's no magic to China's biopharma boom; rather, it is the predictable result of its well-known ability to take commoditized business activities and scale them up.
The path forward for continuing U.S. leadership becomes much clearer with the underlying drivers properly understood.
Author's Summary
U.S. can adapt China's biotech strategy for success.